Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.
馬薩諸塞州劍橋，2024年11月22日（GLOBE NEWSWIRE）——領先的活體生物治療公司Seres Therapeutics, Inc.（納斯達克股票代碼：MCRB）今天宣佈，總裁兼首席執行官埃裏克·沙夫將在美國東部時間2024年12月3日下午4點30分參加派珀·桑德勒第36屆年度醫療保健會議的爐邊談話。
A live webcast of the chat will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at and will be available for replay following the event.
聊天的網絡直播可通過公司網站 「投資者和新聞」 部分的 「活動和演講」 選項卡觀看，並將在活動結束後重播。
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome therapeutic, and which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit .
關於 Seres Therapeut
Seres Therapeutics, Inc.（納斯達克股票代碼：MCRB）是一家臨床階段的公司，致力於通過新的活生物療法改善醫療弱勢群體的患者預後。塞雷斯領導了VoWST的成功開發和批准，這是第一款經美國食品藥品管理局批准的口服微生物組療法，並於2024年9月出售給雀巢健康科學。該公司正在開發 SER-155，在一項針對接受異基因造血幹細胞移植 (allo-HSCT) 的患者的臨床研究中，該藥物已證明血液感染和相關併發症顯著減少（與安慰劑相比）。SER-155 和該公司的其他管道計劃旨在針對多種與疾病相關的途徑，由標準克隆細胞庫通過培育製成，而不是使用用於 VoWST 的捐贈者來源的生產工藝製成。除了 allo-HSCT 外，該公司還打算在其他醫療脆弱患者群體中評估 SER-155 和其他培育的活體生物治療候選藥物，包括自體造血幹細胞移植患者、中性粒細胞減少的癌症患者、CAR-T 接受者、慢性肝病患者、實體器官移植接受者以及重症監護室和長期急性護理機構的患者。欲了解更多信息，請訪問 .
Investor and Media Contacts:
IR@serestherapeutics.com
投資者和媒體聯繫人：
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Carlo Tanzi，博士
肯德爾投資者關係
ctanzi@kendallir.com
This press release was published by a CLEAR Verified individual.
本新聞稿由一位經過CLEAR認證的個人發佈。
